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doi:10.1Objective: Distal esophageal tumors and gastric cardia tumors, although only physically separated by centime-
ters, have different staging systems and are usually treated differently. We hypothesized that gastroesophageal
junction adenocarcinomas (eg, gastric cardia and distal esophageal tumors) were not distinct entities and had sim-
ilar survival.
Methods: Using the Surveillance, Epidemiology, and End Results database (1988–2005), we identified patients
with adenocarcinomas of the distal esophagus (n ¼ 1474) and gastric cardia (n ¼ 192). We performed an unad-
justed survival analysis using the Kaplan–Meier method, and we used a Cox proportional hazards regression model
to adjust for potential confounding covariates. A 2-sided significance level was used for all statistical testing.
Results: Even after adjusting for potential confounding covariates (location, stage, race, cancer-directed surgery,
and radiation therapy), we found no significant difference between distal esophageal and gastric cardia tumors
with regard to overall (hazard ratio, 1.18; 95% confidence interval, 0.99–1.41) and cancer-specific (hazard ratio,
1.09; 95% confidence interval, 0.90–1.31) survival. Both cancer-directed surgery (hazard ratio, 0.45; 95% con-
fidence interval, 0.37–0.54) and radiation therapy (hazard ratio, 0.63; 95% confidence interval, 0.55–0.71) had
a beneficial influence on survival.
Conclusion: Through a large, population-based analysis of gastric cardia and distal esophageal adenocarcinomas,
we found that patients with gastroesophageal junction adenocarcinomas have similar survival rates. Cancer-directed
surgery was beneficial. Adenocarcinomas of the gastroesophageal junction are not distinct entities delineated by
anatomic boundaries and as such should be managed by one skilled in both esophageal and gastric resections.
(J Thorac Cardiovasc Surg 2010;139:43-8)Gastroesophageal junction (GEJ) tumors include both distal
esophageal (DE; Siewert type I) and gastric cardia (GC;
Siewert type II) carcinomas.1 Although they are physically
separated by only a few centimeters, they have distinct Amer-
ican Joint Committee on Cancer (AJCC) staging systems and
are often treated differently.2
The literature lacks large population-based comparisons
of the survival time of patients with DE and GC tumors.
We evaluated a large, US population–based cancer registry
to understand better the implications of tumor location for
patient survival.
MATERIALS AND METHODS
We conducted a retrospective cohort study using the Surveillance, Epi-
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The Journal of Thoracic and Cwith adenocarcinomas of the distal esophagus or GC.3 Our goal was to eval-
uate the effect of tumor location on patients’ overall and cancer-specific sur-
vival times. We collected information on patient characteristics (age, race,
and sex), tumor characteristics (histologic type, grade, stage, and location),
and treatment (whether they underwent cancer-directed surgery, radiation
therapy, or both). For our analysis, we defined cancer-directed surgery as
either esophagectomy or gastrectomy. Although SEER defines locally abla-
tive or excisional procedures as cancer-directed therapy, we did not. Those
patients who were coded as having undergoing ‘‘beam radiation’’ were clas-
sified as having received radiation. The Human Subjects Committee of the
University of Minnesota determined that our study was exempt from formal
review by the Institutional Review Board.Sample Selection
For our analysis, we used the ‘‘digestive diseases other’’ subregistry of
the SEER database (1973–2005). Patients were staged according to the
AJCC Cancer Staging Manual, sixth edition.2 SEER registries began
collecting data on lymph node metastasis in 1988, and therefore this study
represents data collected by the SEER registries from 1988 through 2005.
We excluded information obtained by the Louisiana SEER registry in
2005 because of the negative effect of Hurricane Katrina on data collection.
To select patients for inclusion in our study, we used the following
topography codes (in parentheses) of the International Classification of
Disease for Oncology, third edition,4 for each anatomic location in the
esophagus: distal esophagus (C152 and C155) and GC (C160). Because
few patients with GC tumors have squamous cell carcinomas (3.8% inci-
dence at the GC compared with 41% incidence at the distal esophagus),
we limited our analysis to patients with adenocarcinomas (International
Classification of Disease for Oncology, third edition, morphology codes
4: 8140–8145). We excluded patients with more than 1 primary tumor. Be-
cause they were unlikely to have received aggressive cancer treatment, weardiovascular Surgery c Volume 139, Number 1 43
General Thoracic Surgery Whitson et alGT
S44Abbreviations and Acronyms
AJCC ¼ American Joint Committee on Cancer
DE ¼ distal esophageal
GC ¼ gastric cardia
GEJ ¼ gastroesophageal junction
SEER ¼ Surveillance, Epidemiology, and End
ResultsFIGURE 1. Cancer-specific survival of patients with midthoracic esopha-
geal, distal esophageal, gastric cardia, and gastric body or fundus tumors (P
<.0001, log-rank test; A), as well as those of the gastroesophageal junction,
distal esophageal, and gastric cardia (P¼ .13, log-rank test; B), for all stages
by using the Kaplan–Meier method. In the table along the abscissa, for each
location on the far left, the 3 rows correspond with the number at risk, the
proportion surviving at that time point, and the corresponding 95% confi-
dence interval at that time point. MT, Midthoracic esophagus; DE, distal
esophagus; GC, gastric cardia; GBF, gastric body or fundus.excluded patients with metastatic disease and patients for whom their only
reporting source was a hospice/nursing home, autopsy, or death certificate.
Statistical Analysis
For all analyses, we used SAS 9.1.3 software (SAS Institute, Inc, Cary,
NC). Where appropriate, results are reported as means  standard devia-
tions. Because of a lack of longer-term follow-up data, we censored our sur-
vival analysis at 5 years. To compare unadjusted overall and cancer-specific
survival between histologic groups and between tumor locations, we used
the Kaplan–Meier method. In the SEER databases the survival time coding
is in monthly increments from the date of the diagnosis to either the date of
death, the date last known to be alive, or the follow-up cutoff date of that
particular database edition. To adjust our survival analysis for potential con-
founding variables, we used a Cox proportional hazard regression model.
For all analyses, we used a 2-sided a value of .05.
RESULTS
Sample Description
Of the 237,674 patients in the SEER ‘‘digestive diseases
other’’ subregistry, we identified 1666 patients who met our
inclusion criteria. We initially evaluated the overall aggre-
gate survival of midthoracic esophageal, DE, GC, and gas-
tric body or fundus tumors (Figure 1, A) and found that
the midthoracic esophageal tumors had the worst survival
and gastric body or fundus tumors had the best survival (P
< .0001). When we limited our analysis to those tumors of
the distal esophagus and GC (ie, GEJ tumors), we found
no difference (P ¼ .13) in survival rates (Figure 1, B).
Squamous cell carcinomas of the GC were reported in
only 3.8% of the patients. Therefore we decided to limit
our analysis to adenocarcinomas of the GEJ (Figure 2, A).
For the DE and GC tumors, there was no significant differ-
ence in age, sex, or tumor grade (Table 1). Patients with DE
tumors were more likely to be nonwhite. Patients with GC
tumors were more likely to have stage I and IV disease. In
addition, the patients with GC tumors underwent a signifi-
cantly higher rate of cancer-directed surgery, whereas the
patients with DE tumors had a significantly higher rate of ra-
diation treatment. The mean tumor size in both groups was
just over 5.5 cm. The patients with GC tumors had a higher
number of lymph nodes identified at resection.
Survival
We evaluated the effect of stage on unadjusted overall and
cancer-specific survival rates. To be concise, only the can-
cer-specific survival evaluations are presented in this articleThe Journal of Thoracic and Cardiovascular Surge(Figure 2). Only those patients with stage III disease had sig-
nificantly different survival times (Figure 2, D).
When we stratified our Kaplan–Meier analysis by T stage (in-
stead of AJCC stage), we found no significant differences in
cancer-specific survival rates for DE and GC adenocarcinomas:
T1 (P¼ .79), T2 (P¼ .85), T3 (P¼ .77), and T4 (P¼ .33).
We used a Cox proportional hazard regression model to
adjust for potential confounding variables on overall orry c January 2010
FIGURE 2. Cancer-specific survival, determined by using the Kaplan–Meier method, of patients with gastroesophageal adenocarcinomas for all stages in
aggregate (P ¼ .28, log-rank test; A) and for stage I (P ¼ .27, log-rank test; B), stage II (P ¼ .94, log-rank test; C), stage III (P ¼ .02, log-rank test; D), and
stage IV (P ¼ .45, log-rank test; E). In the table along the abscissa, for each location on the far left, the 3 rows correspond with the number at risk, the pro-
portion surviving at that time point, and the corresponding 95% confidence interval at that time point. DE, Distal esophagus; GC, gastric cardia.
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TABLE 1. Study characteristics by tumor location
Distal esophagus Gastric cardia P value*
No. 1474 192
Age at diagnosis (y) 63.9  11.4 65  12.2 .48
Female/male sex 25%/75% 28.1%/71.9% .35
Race
White 62.5% 72.8% .02
Black 25.5% 19.4%
Other 12.0% 7.9%
Mean size
of tumor (cm)
5.8  5.5 5.6  2.6 .84
Mean no. of positive LNs 0.9  2.1 2.2  3.3 .004
Mean total
no. of LNs
2.4  6.1 5.4  8.8 .06
Cancer-directed surgery
(yes)
26.3% 44.3% <.0001
Radiation therapy (yes) 54.3% 32.6% <.0001
Grade
Well differentiated 5.1% 5.7% .20
Moderately
differentiated
32.1% 32.3%
Poorly differentiated 46.3% 52.1%
Undifferentiated 2.0% 1.6%
Unknown 14.4% 8.3%
AJCC stage
Stage I 3.6% 14.1% <.0001
Stage II 12.1% 5.2%
Stage III 21.3% 7.3%
Stage IV 63% 73.4%
Data are reported as percentages or means and standard deviations. Because of round-
ing, categories might not sum to 100%. LNs, Lymph nodes; AJCC, American Joint
Committee on Cancer. *All P values are for between-group comparisons.
TABLE 2. Cox proportional hazards regression models for overall
and cancer-specific survival analysis of adenocarcinomas of the
gastroesophageal junction*
Variable
All-cause mortality,
HR (95% CI)
Cancer-specific
mortality, HR (95% CI)
Tumor location
Distal esophagus 1.00 (reference) 1.00 (reference)
Gastric cardia 1.18 (0.99–1.41) 1.09 (0.90–1.31)
AJCC stage
Stage I 1.00 (reference) 1.00 (reference)
Stage II 1.4 (0.95–2.07) 1.5 (0.95–2.37)
Stage III 2.92 (2.20–4.24) 3.28 (2.14–5.04)
Stage IV 3.99 (2.76–5.77) 4.62 (3.02–7.08)
Race
White 1.00 (reference) 1.00 (reference)
Black 1.17 (1.02–1.35) 1.19 (1.02–1.38)
Other 0.82 (0.67–1.01) 0.92 (0.74–1.15)
Cancer-directed surgery
No 1.00 (reference) 1.00 (reference)
Yes 0.52 (0.44–0.61) 0.45 (0.37–0.54)
Radiation
No 1.00 (reference) 1.00 (reference)
Yes 0.59 (0.24–1.43) 0.63 (0.55–0.71)
HR, Hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Can-
cer. *Hazard ratios adjusted for cancer registry (data not shown).
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Scancer-specific patient survival rates (Table 2). We found no
significant difference in either overall or cancer-specific sur-
vival rates between patients with DE tumors and patients
with GC tumors. Increasing stage was associated with
a worse prognosis. Both cancer-directed surgery and radia-
tion had a beneficial effect on survival.
DISCUSSION
DE and GC carcinomas have distinct AJCC staging sys-
tems,2 even though they are physically separated by only
a few centimeters and are often classified as arising from
the GEJ. In addition, because these 2 tumors arise near the
confluence of the esophagus and stomach, their optimal
treatment has been debated in part because tumors of the
esophagus and stomach have classically been treated differ-
ently and confer different prognoses. Consequently, various
operative approaches to esophagectomy (ie, transhiatal or
transthoracic)5-7 and gastrectomy (with8 or without9 thora-
cotomy), various margin lengths (5–10 cm),8,10-12 various
extents of lymphadenectomy (1-field [D113,14 or D215,16],
2-field,9,17 or 3-field18,19), and various neoadjuvant and ad-
juvant treatment regimens20-22 have been advocated. There46 The Journal of Thoracic and Cardiovascular Surgeis no consensus regarding the optimal treatment of these
tumors.
Given the heterogeneity of the epidemiologic characteris-
tics and patterns of lymphatic spread of these tumors,
Siewert and Stein devised the following classification
scheme: type I (DE carcinomas), type II (true GC carcino-
mas), and type III (subcardial carcinomas). Their scheme fa-
cilitates the study of these tumors and allows for more
accurate comparison of data between centers.1 Analyses of
the effect of location of GEJ tumors on overall and cancer-
specific survival in the literature have been limited to
single-institution series. Therefore we used a large, popula-
tion-based cancer registry to assess the influence of tumor
location on survival rates for patients with adenocarcinomas
of the GEJ.Sample Model
After adjusting for potential confounding covariates (in-
cluding histologic type and stage), we found that the survival
rates for adenocarcinomas of the distal esophagus (type I)
and GC (type II) were similar. For patients who are potential
candidates for curative resection, treatment should be tai-
lored to achieve an R0 resection (including appropriate mar-
gins) and an adequate lymphadenectomy.
Our results are in agreement with those of other studies in
the literature that examined the association between GEJ tu-
mor location and patient survival rates. Wijnhoven and col-
leagues23 performed a retrospective review of 252 patients
with DE or GC adenocarcinomas who underwentry c January 2010
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cember 1996. In their multivariate analysis they found no
significant difference in survival rates between patients
with DE tumors and patients with GC tumors. In a series
of more than 1000 consecutive patients, Siewert and associ-
ates9 noted no significant difference in survival rate between
patients with DE tumors (Siewert type I) and patients with
GC tumors (Siewert type II). Unlike our study, however,
Siewert and associates noted that patients with gastric
body or fundus tumors (Siewert type III) had a significantly
worse prognosis than patients with DE tumors or patients
with GC tumors.
Interestingly, in our study there were a greater number of
lymph nodes identified in patients with GC tumors than in
patients with esophageal tumors. This difference might be
due to more completely defined practice guidelines for an
adequate lymphadenectomy for gastric carcinomas; a D1
dissection should be performed in which at least 15 lymph
nodes are examined.13,14 In contrast, guidelines for manag-
ing lymph nodes in patients with esophageal cancer are lack-
ing. We speculate that the differences in the total number of
lymph nodes identified is likely a function of the difference
in staging systems in which pathologists are encouraged to
evaluate 15 nodes for gastric cancers (and no such criteria
exist for esophageal carcinomas). In the gastric cancer stag-
ing system up to 6 positive nodes is still considered N1 dis-
ease. In the esophageal staging system this is not the case. In
the esophagus node number and location have the potential
for rapid spread because of a rich lymphatic network and
lack of serosa. Another factor that might affect the resection
rate as well is that in patients with gastric cancer, a clinically
positive perigastric lymph node would not preclude primary
surgical resection. However, a similar patient with a perieso-
phageal node clinically positive at the distal esophagus
would be in a higher stage and currently treated differently.Limitations
Our study has several limitations, some of which are in-
herent limitations of the SEER database. The SEER database
does not collect data on a number of important prognostic
variables, including comorbidities, hospital volume, and
use of chemotherapy.20-22 Therefore we could not adjust
for these variables in our survival analysis. It is possible
that tumor location might have been misclassified in patients
who did not undergo esophagectomy or gastrectomy
because the SEER database does not mandate endoscopic
validation. We used the AJCC staging systems in our multi-
variate survival analysis. However, DE and GC adenocarci-
nomas have different AJCC staging systems, which could
confound our results.2 When we used the SEER historic
staging system, our results were unchanged, indicating that
the differences in AJCC staging were not a significant source
of confounding.The Journal of Thoracic and CCONCLUSIONS
Through a large, population-based analysis of the SEER
database, we found that DE and GC adenocarcinomas
have similar overall and cancer-specific patient survival
rates. This argues that adenocarcinomas of the GEJ are not
distinct entities delineated by anatomic boundaries. We
recommend that the same surgical oncology principles
(adequate staging, en bloc resection with appropriate mar-
gins, and an adequate lymphadenopathy) should be applied
to the treatment of tumors of both locations.
We thank Mary Knatterud, PhD, for her editorial assistance with
this manuscript.References
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